treatment with DIELEN Protect

Phase 2Small molecule

treatment with DIELEN Protect is one of 35 small molecule programs targeting Irritable Bowel Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Irritable Bowel SyndromeRecruiting

Irritable Bowel SyndromePhase 2

Recruiting

Competition

Competitive Landscape

43 competitors in Irritable Bowel Syndrome

#DrugCompanyPhaseTrials

Linzess

AbbVie

Approved

12 2

Resotran

Takeda

Approved

2 3

Cymbalta

Jazz Pharmaceuticals

Approved

2 4

Lexapro

AbbVie

Approved

1 5

Nurtec

Pfizer

Approved

1 6

Golytely

Azulfidine

Alinia

RRomark Laboratories L.C.

Approved

2 9

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 10

Trental

VValidus Pharmaceuticals

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Irritable Bowel Syndrome

NCT07039747

Q2 2032

Phase 3Not yet recruiting

Colorectal Cancer

NCT06446557

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer

Not yet recruiting·UUniversity Hospital, Rouen·Phase 3·NCT06446557·408 enrolled

Irritable Bowel Syndrome1 trial

Effectiveness of a Dietary Supplement in Irritable Bowel Syndrome

Recruiting·UUniversity Hospital, Rouen·Phase 2·NCT07039747·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for treatment with DIELEN Protect. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — treatment with DIELEN Protect compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for treatment with DIELEN Protect. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Rouen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Hospital, Rouen

treatment with DIELEN Protect

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2032

Trials by Indication[1]

Colorectal Cancer1 trial

Irritable Bowel Syndrome1 trial

References

Drug Info

Quick Facts

Related News